Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.

This case report describes how changing treatment from adalimumab to guselkumab successfully controlled both pustulotic arthro-osteitis and paradoxical skin reactions in a patient with palmoplantar pustulosis.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials.

This review suggests that IL-23 inhibitors may be effective for various non-psoriatic inflammatory skin conditions, but emphasizes the need for further large-scale trials to confirm their efficacy and safety.

This review summarizes recent developments in dermatology, including advancements in imaging techniques, biologics, and controversies in treatment, but presents no new clinical findings.

This guideline reviews the diagnosis and treatment of malignant cutaneous angiosarcomas, highlighting the complexity of treatment and the importance of early detection despite non-specific clinical presentations.

This study reviews advances in targeted therapies for moderate-severe dermatological conditions like plaque psoriasis and atopic dermatitis, reporting on newly approved treatments and highlighting the need for further innovations in managing rare inflammatory skin diseases through emerging laboratory techniques and trials.

This case report from the provided study details a previously unreported adverse effect of salivary gland inflammation potentially linked to acitretin therapy for generalized pustular psoriasis, suggesting further research is needed to explore this association.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

This study found that locally injected zalutumumab in healthy volunteers induced a papulopustular rash similar to systemic EGFR inhibitors, and that IL-8 inhibition reduced this dermatological side effect.

Ixekizumab effectively treats generalized pustular psoriasis.

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.

This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.

This review summarizes 15 years of clinical and experimental research advancements in hidradenitis suppurativa, highlighting its recognition as a uniquely healable inflammatory skin disease but reports no new clinical results.

This review discusses the complex causes and treatment challenges of chronic inflammatory skin diseases, emphasizing the need for biomarkers to predict treatment responses; it reports no new clinical results.

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

This systematic review reports that for patients with underlying dermatologic disorders who contracted COVID-19, most experienced mild to moderate exacerbation of their skin conditions and were managed similarly to the general population, suggesting treatment discontinuation during acute infection may prevent severe recurrence.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

In this scoping review, researchers found that while some dietary approaches may help improve psoriasis symptoms—particularly in those with obesity or coeliac disease—the overall evidence is limited, and larger studies are necessary to identify effective diets for the broader psoriasis population.

This study reviewed and categorized dermatological drugs for pregnancy and lactation according to new FDA labeling guidelines, which replaced simplistic letter categories with detailed information, aiming to improve prescribing decisions by addressing both maternal and paternal reproductive potential.

This case report describes a 37-year-old woman who developed scalp psoriasis and severe alopecia after taking adalimumab, with complete hair regrowth following treatment change.

This review discusses the clinical guidelines for hidradenitis suppurativa, detailing its definition, impacts, and treatments, and includes a proposed therapeutic approach algorithm, but reports no new clinical findings.

In this case report, a 64-year-old woman developed alopecia areata after starting the IL-17A inhibitor secukinumab for psoriasis, highlighting a potential rare side effect of this treatment, with only three similar cases reported in the literature.

This review discusses the benefits and applications of microsponges delivery systems in drug delivery, particularly for topical treatments, and reports no new clinical findings.

This study reported that AutoML effectively modeled itching and pain development, as well as app use, in patients with chronic eczema or psoriasis using a smartphone monitoring app, revealing that factors like BMI, age, and disease activity significantly influenced app engagement.

This case report describes a 50-year-old woman with palmoplantar psoriasis who developed alopecia areata after starting tildrakizumab, suggesting a possible paradoxical reaction related to the medication.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.